Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT01349933Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of MK-2206 in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Primary endpoints: Proportion of Patients Alive and Progression-free at 6 months and Confirmed Response Rate at 6 months. Started Apr 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01349933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349933.